P

Parkinson's Disease and Movement Disorders Center of Boca Raton | Boca Raton, FL

Research site
(Unclaimed)
Location
951 NW 13th Street, Bldg. 5E, Boca Raton, Florida, United States of America

Site insights

Top conditions

Top treatments

Levodopa
ABBV-951
ENT-01
PF-06649751
Carbidopa
APL-130277
CVN424
Pimavanserin
Midodrine
Prasinezumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

16 of 66 total trials

A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

This is a Phase 2a study to assess the safety and tolerability of TPN-101 patients with PSP.

Active, not recruiting
Progressive Supranuclear Palsy
Drug: Placebo
Drug: TPN-101, 100 mg/day

In this study, researchers will learn more about a study drug called BIIB122 in participants with early-stage Parkinson's disease (PD). In this study...

Enrolling
Parkinson Disease
Drug: BIIB122
Drug: BIIB122-Matching Placebo

This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab...

Active, not recruiting
Parkinsons Disease
Drug: Prasinezumab
Drug: Placebo

This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX00...

Active, not recruiting
Parkinson's Disease
Drug: RO7046015
Drug: Placebo

ORION Trial is a trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of a rand...

Enrolling
PSP
Neurodegenerative Diseases
Other: Placebo
Drug: AMX0035

The goal of this clinical study is to compare Felix NeuroAI Wristband and sham device in patients with essential tremor. The main question it aims to...

Enrolling
Essential Tremor
Device: Felix NeuroAI Wristband
Device: Sham Device

This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placeb...

Enrolling
Parkinson Disease
Dyskinesia, Drug-Induced
Drug: Dipraglurant
Drug: Placebo

This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD)....

Enrolling
Parkinson's Disease
Drug: Placebo
Drug: CVN424 150 mg

The purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical mea...

Enrolling
Parkinson's Disease
Drug: Placebo
Drug: BIA 28-6156 60 mg

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot fr...

Active, not recruiting
Parkinson's Disease (PD)
Drug: ABBV-951

The objective of this randomized, double-blinded, placebo-controlled Phase 1 investigation is to evaluate the safety and potential clinical effect of...

Enrolling
Multiple System Atrophy
Procedure: Sham (Placebo) Surgery
Biological: AAV2-GDNF gene therapy
Locations recently updated

This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and sy...

Enrolling
MSA - Multiple System Atrophy
Symptomatic Neurogenic Orthostatic Hypotension
Drug: Ampreloxetine
Drug: Placebo

A 76-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 76 we...

Active, not recruiting
Alzheimer Disease
Drug: Placebo
Drug: Simufilam

This is a double-blinded, controlled, randomized clinical trial (RCT) to establish the safety and efficacy of a non-invasive neuromodulation device f...

Enrolling
Parkinson Disease
Parkinson's Disease and Parkinsonism
Device: Non-invasive brainstem stimulation

Upper limb essential tremor (UL ET) is a movement disorder characterized by postural and/or kinetic tremor. It can cause difficulty with everyday tas...

Active, not recruiting
Upper Limb Essential Tremor (UL ET)
Drug: Placebo for BOTOX
Biological: BOTOX

Multi-center, randomized, double-blind, placebo-controlled, 6- month study in subjects with mild to moderate Dementia with Lewy Bodies.

Active, not recruiting
Dementia With Lewy Bodies
Drug: CT1812

Trial sponsors

AbbVie logo
Pfizer logo
Sumitomo Pharma logo
E
Ipsen logo
Roche logo
Acadia Pharmaceuticals logo
C
F
I

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems